All News

Found 9,493 articles

• Altair Nanotechnologies Signs Agreement With Eli Lilly and Company

  5/2/2006

• Ignite Health Wins Interactive Agency Assignment From Cephalon, Inc. Oncology

  5/2/2006

• Emisphere Technologies, Inc. To Receive Milestone Payment For eligen(R) Technology To Be Used In New Development Program

  5/1/2006

• Cleveland Clinic to Host National Summit on Biomedical Conflicts Of Interest Sept. 20

  5/1/2006

• Sigma-Aldrich Corporation Sponsors Full-Text Article On High Content Viral Library Screens

  4/27/2006

• Amylin Pharmaceuticals, Inc. Reports First Quarter Financial Results

  4/27/2006

• Strategic Research Institute Release: The World Antibody Community To Convene At Antibody Manufacturing & Production Conference June 12-14, 2006 In San Francisco, CA

  4/27/2006

• Eli Lilly and Company And Alkermes Initiate Additional Phase 3 Study For Inhaled Insulin As Part Of Comprehensive Registration Program

  4/26/2006

• U.S. Federal District Court In Indianapolis Orders Eli Lilly and Company To Assign Intellectual Property To Emisphere Technologies, Inc.

  4/26/2006

• PPD, Inc. Names Thomas Rosanske Executive Director Of Product Development Analytical Services

  4/26/2006

• Sigma-Aldrich Corporation Initiates RNAi Partnership Program With Rutgers University

  4/25/2006

• Biosite Incorporated Announces Results For The First Quarter Of 2006

  4/25/2006

• Eli Lilly and Company Declares Second-Quarter Dividend

  4/25/2006

• Acting FDA Commissioner To Deliver Keynote Address At IBC Life Sciences's 11th Annual Drug Discovery Technology(R) & Development World Congress

  4/25/2006

• ViroPharma Incorporated Announces Approval Of Third Party Manufacturing And Supply Chain For Vancocin

  4/20/2006

• Amylin Pharmaceuticals, Inc. Announces BYETTA Revenue

  4/20/2006

• Eli Lilly and Company Reports Q1 EPS Of $.77, Or 13% Growth

  4/20/2006

• Lilly ICOS LLC Reports Results For First Quarter Of 2006

  4/20/2006

• Acrux Limited Awarded 1st European Patent

  4/19/2006

• Eli Lilly and Company Statement On STAR; Drug Cuts Breast Cancer Risk, Fewer Side-Effects

  4/18/2006